Efficacy News and Research

RSS

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

In a new study, published in this week's issue of the journal Science, researchers show for the first time how the brain re-wires and fine-tunes its connections differently depending on the relative timing of sensory stimuli.

29 May 2014

Research shows how brain distinguishes specific voices in noisy, distracting environments

Listening to a conversation in the context of a cocktail party presents a great challenge for the auditory system.

29 May 2014

Noninvasive laser therapy triggers stem cells to repair enamel of teeth

A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine.

29 May 2014

Researchers receive $1.5M grant to lower rates of cervical cancer among incarcerated women

Researchers at the University of Kansas Medical Center will use a $1.5 million grant from the National Cancer Institute to examine ways to lower the rates of cervical cancer among incarcerated women.

29 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).

28 May 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Researchers develop active agents that may improve healing of inflammatory illnesses

It is something like the police force of our body: the immune system. It disables intruding pathogens, it dismantles injured tissue and boosts wound healing. In this form of 'self-defense' inflammatory reactions play a decisive role.

27 May 2014

Griffith, Blackmores Institute launch special online course on complementary medicines

Pharmacists and other healthcare professionals will have the opportunity to boost their knowledge of complementary medicines when Griffith University and Blackmores Institute launch a special online course.

27 May 2014

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain.

27 May 2014

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency).

27 May 2014

Allergists warn e-smokers of unknown risks

Caveat emptor - or "buyer beware" holds true when it comes to the unknown health effects of e-cigarettes. An article in the June issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), examines risks, including the ongoing dependence on nicotine and the dual use of e-cigarettes and regular cigarettes.

27 May 2014

Study: Sufficient copies of SMN1 gene extend survival in animals with spinal muscular atrophy

To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA.

23 May 2014

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week.

23 May 2014

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

PTC Therapeutics, Inc. today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.

23 May 2014

New report raises important questions about transcranial direct current stimulation

Over the past several decades, neurostimulation techniques such as transcranial direct current stimulation (tDCS) have gradually gained favour in the public eye. In a new report, published yesterday in the prestigious scientific journal Neuron, IRCM ethics experts raise important questions about the rising tide of tDCS coverage in the media, while regulatory action is lacking and ethical issues need to be addressed.

23 May 2014

Study examines potential use of medical marijuana, CBD in treating epilepsy

The therapeutic potential of medical marijuana and pure cannabidiol (CBD), an active substance in the cannabis plant, for neurologic conditions is highly debated.

23 May 2014

Can cannabis help curb convulsions?

Experts say that vigorous investigations are needed to determine whether or not the medical use of marijuana would be of benefit to patients with epilepsy.

22 May 2014

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Decision Resources Group finds that, when asked to indicate the relative importance of product attributes when prescribing a new drug for Crohn's disease (CD), the highest percentages of surveyed gastroenterologists in the United States and Europe selected efficacy over safety and tolerability or delivery.

22 May 2014

Efficacy News and Research

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

Research shows how brain distinguishes specific voices in noisy, distracting environments

Noninvasive laser therapy triggers stem cells to repair enamel of teeth

Researchers receive $1.5M grant to lower rates of cervical cancer among incarcerated women

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Researchers develop active agents that may improve healing of inflammatory illnesses

Griffith, Blackmores Institute launch special online course on complementary medicines

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Allergists warn e-smokers of unknown risks

Study: Sufficient copies of SMN1 gene extend survival in animals with spinal muscular atrophy

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

New report raises important questions about transcranial direct current stimulation

Study examines potential use of medical marijuana, CBD in treating epilepsy

Can cannabis help curb convulsions?

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News